Studienpraxis Heimeranplatz

Research site

Germany Heimeranplatz 2, 80339 Munich, Germany

2 trials recruiting
Pharyngitis · COVID-19 · Pneumonia respiratory syncytial viral
Adults and children

About Specializations

Studienpraxis Heimeranplatz in Munich, Germany specialises in clinical trials of conditions such as Pharyngitis, COVID-19, Pneumonia respiratory syncytial viral, Respiratory syncytial virus bronchiolitis, and other specialisations. This site conducts important research.

Main research areas of the site

Otorhinolaryngologic Diseases

At Studienpraxis Heimeranplatz in Munich, the clinical research focus is centered on otorhinolaryngologic diseases, with studies looking at the treatment of acute pharyngitis. The trials are designed to assess whether a lozenge-based therapy can help relieve symptoms effectively and provide better patient outcomes than comparison treatments or placebo.

Symptomatic treatment research for acute pharyngitis
Evaluation of benzydamine hydrochloride and dichlorobenzyl alcohol for throat symptom relief
Testing treatment effectiveness against active comparators and placebo

The site contributes to practical, patient-focused research in ear, nose, and throat medicine, with an emphasis on finding reliable options for easing sore throat symptoms.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Heimeranplatz 280339 MunichGermany

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 6

More sites in Munich Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

5 clinical trials

Pharyngitis

Recruiting

Testing benzydamine hydrochloride and dichlorobenzyl alcohol lozenges for relief of sore throat symptoms in patients with acute pharyngitis

Registered drug

Testing benzydamine hydrochloride and dichlorobenzyl alcohol lozenges for relief of sore throat symptoms in patients with acute pharyngitis

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:2,4 dichlorobenzyl alcohol
Sponsor:MEDICE Arzneimittel Puetter GmbH & Co. KG

Contact Research Centre

COVID-19

Recruiting

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Ibuzatrelvir
Sponsor:Pfizer Inc.

Contact Research Centre

Pharyngitis

Not yet recruiting

Study of benzydamine hydrochloride and dichlorobenzyl alcohol lozenges for treating acute pharyngitis symptoms

Registered drug

Study of benzydamine hydrochloride and dichlorobenzyl alcohol lozenges for treating acute pharyngitis symptoms

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:2,4 dichlorobenzyl alcohol
Sponsor:MEDICE Arzneimittel Puetter GmbH & Co. KG

Contact Research Centre

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
Sponsor:GlaxoSmithKline Biologicals

Contact Research Centre

Study on the Safety and Immune Response of RSVPreF3 Vaccine for Respiratory Syncytial Virus in Adults Aged 60 and Above

Not recruiting

Registered drugNo placebo

Study on the Safety and Immune Response of RSVPreF3 Vaccine for Respiratory Syncytial Virus in Adults Aged 60 and Above

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
Sponsor:GlaxoSmithKline Biologicals

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites